featured
Trastuzumab Biosimilar vs Reference Trastuzumab in the Neoadjuvant Setting for HER2-Positive Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
European Journal of Cancer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Three-Year Follow-Up From a Phase 3 Study of SB3 (a Trastuzumab Biosimilar) Versus Reference Trastuzumab in the Neoadjuvant Setting for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
Eur. J. Cancer 2019 Oct 01;120(xx)1-9, X Pivot, M Pegram, J Cortes, D Lüftner, GH Lyman, G Curigliano, I Bondarenko, YC Yoon, Y Kim, C KimFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.